ArticleCurrent oncology (Toronto, Ont.)2023

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy.

Markus Falk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.